IDiyas

For the Inventor, By the Inventor

San Antonio, TX, United States of America

Wouter Koek

USPTO Granted Patents = 13 

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 93(Granted Patents)


Location History:

  • Viviers-les-Montagnes, FR (1997 - 2002)
  • San Antonio, CA (US) (2008)
  • San Antonio, TX (US) (2007 - 2012)

Company Filing History:

goldMedal13 out of 266 
 
Pierre Fabre Medicament
 patents

Years Active: 1997-2012

Loading Chart...
13 patents (USPTO):Explore Patents
1. 8106074 - Pyridin-2-yl-methylamine derivatives for treating opiate dependence (2012-01-31),
2. 7456192 - 3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof (2008-11-25),
3. 7235568 - 3-(cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia (2007-06-26),
4. 7163957 - 3-(Cyclopenten-1-yl)-benzyl-or 3-(cyclopenten-1-yl)-heteroarylmethyl-amine derivatives and use thereof as medicines for treating schizophrenia (2007-01-16),
5. 6448268 - Aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-ht1 receptor antagonists (2002-09-10),
6. 6417222 - [2-substituted-5-[3-thienyl)-benzyl]-2- ([2-isopropoxy-5-fluoro]-phenyoxy)-ethyl]-amine derivatives, method for the production and use thereof as medicaments (2002-07-09),
7. 6350913 - 3-alkoxybenzylamine derivatives and their use as medicines for treating schizophrenia (2002-02-26),
8. 6303603 - 3-oxo-2(H)-1,2,4-triazine derivatives as ligands of 5 HT1A receptors (2001-10-16),
9. 6191130 - Cyclohexane derivatives difunctionalised in 1,4 as ligands of 5T H1A receptors (2001-02-20),
10. 6020345 - Pyridin-2-yl-methylamine derivatives, method of preparing and (2000-02-01),
11. 5977106 - 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives (1999-11-02),
12. 5958945 - Naphthamide derivatives of 3-beta-amino azabicyclo octane or nonane as (1999-09-28),
13. 5591743 - 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives as 5HT.sub.1A ligands (1997-01-07),

Title: Wouter Koek: A Pioneer in Opioid Dependence Treatments

Introduction

Wouter Koek is a distinguished inventor based in San Antonio, TX, with an impressive portfolio of 13 patents to his name. Known for his innovative contributions to the field of medicinal chemistry, Koek's work focuses on developing novel compounds aimed at treating opiate dependence and associated conditions.

Latest Patents

Among his latest inventions, Koek has developed two significant patents. The first patent, titled "Pyridin-2-yl-methylamine derivatives for treating opiate dependence," centers on the application of specific compounds to address opioid drug dependence. This invention specifically targets hyperalgesia and psychological cravings resulting from opiate withdrawal.

The second patent, "3β-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof," introduces innovative compounds represented by a complex general formula. These compounds feature a bicyclic fused heteroaromatic structure that serves as anti-dopaminergic agents, showcasing potential efficacy in therapeutic applications.

Career Highlights

Wouter Koek has made significant strides in his career, particularly during his tenure at Pierre Fabre Medicament. His vast knowledge and expertise in drug design and development have led to tangible advancements in therapeutic solutions for treating addiction and associated psychological challenges.

Collaborations

Collaboration plays a crucial role in Koek's innovative journey. He has had the privilege of working alongside notable colleagues, including Bernard Vacher and Elisabeth Dupont-Passelaigue. Together, they continue to push the boundaries of scientific discovery in the pursuit of effective treatment options.

Conclusion

Wouter Koek stands out as a prominent inventor dedicated to addressing the pressing issues surrounding opiate dependence. With a solid foundation of patents and ongoing collaborative efforts, Koek's contributions are poised to make a lasting impact on the field of medicinal chemistry and public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…